RxDoctor Payments Data

Genean Doyle

Family · Camden, NJNPI 1336551456

Payments from drug & device makers

$943in general payments, 2019–2025

Across 41 payments — averaging $23.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$226
  • Abbott$177
  • Boehringer Ingelheim$131
  • Braeburn Inc.$100
  • Alkermes, Inc.$91
  • Merck$31
  • plus $187 from 8 others

What the payments were for

  • Food & beverage$91597%
  • Other$283%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$943 in reported general payments places this provider in the 75th percentile of 2,692 family providers in New Jersey.

See all family providers in New Jersey

Medicare billing

Part B allowed, 2024
$128
Medicare patients
14
Services billed
19

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide17$16,499
JardianceEmpagliflozin20$15,427
Bydureon BciseExenatide Microspheres14$12,011
JanumetSitagliptin Phos/Metformin Hcl11$5,409
Albuterol Sulfate HfaAlbuterol Sulfate74$1,308
Omeprazole69$915
Colchicine11$778
Gabapentin51$724
Amlodipine Besylate125$697
Metformin Hcl128$676
Atorvastatin Calcium126$672
Levothyroxine Sodium67$456
Losartan Potassium57$426
Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med12$416
Trazodone Hcl27$379

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$15$16,49917 claims
Boehringer IngelheimJardiance$131$15,42720 claims
MerckJanumet$31$5,40911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,692 family providers in New Jersey.

Other family in Camden

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →